Additional file 3: Seventeen Candidate genes P value Fold Reported gene character

change

1.75

1.79

1.53

1.80

1.51

1.88

1.50

1.57

1.97

1.64

1.57

1.52

0.001581

0.002094

0.002243

0.003200

0.003200

0.003961

0.007427

0.008633

0.012791

0.020715

0.039616

0.041573

Gene

symbol

PROX1

S100A2

INTS6

CHRM3

KCNJ2

HMGA2

BMP4

PHLDA1

IGF2

DACH1

COL11A1

DACT1

Gene title

regulation of nuclear pre-mRNA domain

prospero-related homeobox 1

S100 calcium binding protein A2

cholinergic receptor, muscarinic 3

high mobility group AT-hook 2

bone morphogenetic protein 4

insulin-like growth factor 2

dachshund homolog 1

collagen, type XI, alpha 1

potassium inwardly-rectifying channel,

pleckstrin homology-like domain, family A,

dapper, antagonist of beta-catenin, homolog

integrator complex subunit 6

subfamily J, member 2

member 1

RPRD1A	containing 1A	0.000744	1.68	RPRD1A inhibits the Wnt/ β -catenin signaling pathway. (29)
TESC	tescalcin	0.000773	1.71	The EF-hand calcium-binding protein. TESC may interract with NF-кВ and colorectal cancer. (30)
ATF6	activating transcription factor 6	0.001125	1.53	A missense polymorphism in ATF6 gene is associated with hepatocellular carcinoma. (31)
ZBED6	zinc finger, BED-type containing 6	0.001207	1.55	Transcriptional modulator ZBED6 affects cell cycle and growth of human colorectal cancer cells. (32)
TNIK	Traf2- and NCK- interacting kinase	0.001370	1.58	TNIK is essential for Wnt signaling and colorectal cancer growth. (11)

cancer. (33)

carcinoma. (36)

(39)

(43)

(44)

Ras/MAPK pathway. (37)

17-5p in hepatocellular carcinoma. (35)

nasopharyngeal carcinoma patients. (38)

PROX1 is a specific target of the β -catenin/TCF pathway in the intestinal epithelium. PROX1

is upregulated in colorectal cancer, and may have a role in tumor progression in colorectal

Pseudogene INTS6P1 regulates its cognate gene INTS6 through competitive binding of miR-

CHRM3 is a novel prognostic factor of poor prognosis in patients with endometrial

Upregulation of the inwardly rectifying potassium channel Kir2.1 (KCNJ2) modulates

multidrug resistance of small-cell lung cancer under the regulation of miR-7 and the

High-mobility group A2 overexpression is an unfavorable prognostic biomarker for

BMP4 inhibits breast cancer metastasis by blocking myeloid-derived suppressor cell activity.

PHLDA1 is a crucial negative regulator and effector of Aurora A kinase in breast cancer. (40)

High IGF2 expression is associated with poor clinical outcome in human ovarian cancer. (41)

COL11A1 promotes tumor progression and predicts poor clinical outcome in ovarian cancer.

Expression and epigenetic regulation of DACT1 and DACT2 in oral squamous cell carcinoma.

Silencing DACH1 promotes esophageal cancer growth by inhibiting TGF-β signaling. (42)

S100A2 is a predictive biomarker of pancreatic adenocarcinoma. (34)